Norwegian MRS (magnetic resonance spectroscopy) to improve cancer diagnosis
This article was originally published in Clinica
Executive Summary
A Norwegian research group claims to be the first to be the first to use in vivo magnetic resonance spectroscopy (MRS) to differentiate between benign and cancerous breast lesions in patients. The group, headed by Ingrid Gribbestad, senior research scientist at the Foundation for Scientific and Industrial Research at the Norwegian Institute of Technology in Trondheim, is using MRS to specifically document the presence of chemical substances in cancerous tumours.